Form 4: TuHURA Biosciences Director Alan List Reports Option Grant

Director Alan List reports receiving an option grant for 51,275 shares of TuHURA Biosciences common stock.

Summary

• Alan List, a director of TuHURA Biosciences, Inc., filed a Form 4 to report a transaction.
• On January 2, 2025, List was granted options to purchase 51,275 shares of common stock at an exercise price of $4.11.
• These options vest in three equal installments on the first, second, and third anniversaries of the grant date, expiring on January 2, 2035.
• Following the transaction, List directly owns options for 51,275 shares.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation event, which is generally neutral to positive as it incentivizes management. There is nothing to suggest negative sentiment.

Positives

• The option grant aligns the director's interests with those of the shareholders, incentivizing him to work towards increasing the company's value.

Industry Context

Option grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Director compensation packages, including option grants, vary significantly across the biotechnology industry depending on company size, stage of development, and performance.
• Comparing the size and vesting schedule of this option grant to those of directors at comparable companies like Iovance Biotherapeutics or Adaptimmune Therapeutics would provide a benchmark for assessing its competitiveness.

Stakeholder Impact

• The option grant could potentially benefit shareholders if the director's performance leads to an increase in the company's stock price.

Key Dates